October 2012

Mesothelioma and Other Rare Diseases: Forging Alliances to Make a Greater Impact

National Organization for Rare Diseases (NORD) and the Drug Information Association held their 2nd Annual Conference –  the US Conference on Rare Diseases and Orphan Products: Shaping the Future Now. The Meso Foundation was in attendance representing mesothelioma and the meso community.
Sessions focused on advocacy for inclusion of patients and community members in the research […]

Using the Measles Virus to Treat Mesothelioma

Last night, Dr. Tobias Peikert of the Mayo Clinic joined us on a conference call, as part of the Meso Foundation’s Meet the Experts series, to discuss an exciting new clinical trial. The trial, which uses the measles virus to attack the mesothelioma cells, is currently enrolling pleural mesothelioma patients regardless of whether they’ve undergone prior therapy. […]

Mesothelioma Awareness Events Recap

With this past weekend’s “Miles for Meso” Bike Run fundraiser, the events surrounding Meso Awareness Day have officially concluded for 2012! (Though awareness-building is far from over – continue checking our website for additional events coming up in November). This year, we are excited to report that in August, September and October, Meso Foundation supporters […]

Meso Foundation Clinical Trial Consortium for Faster Advancement of Mesothelioma Research

by Lee M. Krug, MD
At the International Mesothelioma Interest Group Meeting in Boston, a group of investigators convened at a Clinical Trials Design Workshop to discuss the challenges of conducting trials in this disease. The rarity of mesothelioma poses various issues with regards to proper study design, accrual, and interest by pharmaceutical companies. One theme […]

NIH Announces They Expect to Fund Grants at 90%

Last week, the National Institutes for Health (NIH) issued a notice stating non-competing research grant awards will be funded below the level indicated in the most recent Notice of Award, or “generally up to 90% of the previously committed level,” until the FY 2013 appropriations are enacted. This means that all researchers, including those involved in […]